In about one quarter of the cases, however, the mutation is not inherited but occurs spontaneously.
This mutation is not actually in a gene, though.
Developing a gene therapy for each and every mutation is not practical, says Hauswirth.
The bitter irony is that human mutation is not a binary yes/no condition, but a whole spectrum.
Generally, one mutation is not enough to cause cancer; the disease does not develop until other mutations occur.
However, the mechanistic basis of lasR mutation is not well understood.
The results of the current experiment provide evidence that the corpulent mutation is not fully characterized in one strain.
The results indicate that p53 mutation is not significantly associated with tumor grade, age, or gender (p > 0.05).
However, several recent studies have suggested that BRAF mutation is not associated with poor prognosis of PTC.
For example, the anomalous response of FNfn10 to mutation is not solely a property of the core as we had previously suggested.
This raises the suggestion that there are tumour suppressor genes for which a mutation is not requisite for inactivation, but rather, inactivation is achieved through miRNA-mediated repression or methylation-mediated repression alone.
